Stars Align For AstraZeneca In JUPITER Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca halts Crestor study early after cardiovascular morbidity and mortality is reduced in patients with elevated C-reactive protein.
You may also be interested in...
AstraZeneca’s JUPITER Study Brings Challenges For Crestor Marketing
AstraZeneca and its cholesterol-lowering agent Crestor scored a clear coup Nov. 9, when results of the widely-publicized JUPITER trial were announced at the American Heart Association meeting. The firm's ability to maximize the potential of the findings, however, presents multiple marketing challenges
AstraZeneca’s JUPITER Study Brings Challenges For Crestor Marketing
AstraZeneca and its cholesterol-lowering agent Crestor scored a clear coup Nov. 9, when results of the widely-publicized JUPITER trial were announced at the American Heart Association meeting. The firm's ability to maximize the potential of the findings, however, presents multiple marketing challenges
AstraZeneca’s Oral Anticoagulant AZD0837 Phase III Program Pushed Back To 2009
Backup compound to AstraZeneca’s failed Exanta is being investigated for a stability limitation; Crestor is the only branded statin to increase U.S. market share during 2008.